Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study

REGAIN Study Group

Research output: Contribution to journalArticlepeer-review

206 Scopus citations

Fingerprint

Dive into the research topics of 'Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study'. Together they form a unique fingerprint.

Medicine & Life Sciences